Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine
Gajanan Sapkal, Rajni Kant, Gaurav Raj Dwivedi, Rima R. Sahay, Pragya D. Yadav, Gururaj Deshpande, Rajeev Singh, Dimpal A. Nyayanit, Deepak Y. Patil, Anita Shete-Aich, Kamran Zaman, Anil K Chaudhari, Nivedita Gupta, Samiran Panda, Priya Abraham, Balram Bhargava
Abstract
Comparative analysis at 1- and 6-month post-vaccination showed modest reduction in S1-RBD IgG antibody and NAb titers against B.1, Alpha, Beta and Delta variants in heterologous and homologous vaccine recipients groups. However, significant reduction in NAb titers against Omicron in vaccinees’ sera post-6 months underlines need for cautious prospective follow-up.
Topics & Concepts
HeterologousMedicineVirologyTiterCoronavirus disease 2019 (COVID-19)VaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakImmune systemAntibodyImmunologyNeutralizing antibodyVirusBiologyDiseaseInfectious disease (medical specialty)Internal medicineGeneGeneticsOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies